0001567619-20-004636.txt : 20200221
0001567619-20-004636.hdr.sgml : 20200221
20200221181635
ACCESSION NUMBER: 0001567619-20-004636
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200219
FILED AS OF DATE: 20200221
DATE AS OF CHANGE: 20200221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Viret Jean-Frederic
CENTRAL INDEX KEY: 0001427569
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36721
FILM NUMBER: 20641486
MAIL ADDRESS:
STREET 1: ANESIVA, INC.
STREET 2: 650 GATEWAY BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Coherus BioSciences, Inc.
CENTRAL INDEX KEY: 0001512762
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273615821
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O DENNIS M. LANFEAR
STREET 2: 333 TWIN DOLPHIN DR, SUITE 600
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: (650) 649-3530
MAIL ADDRESS:
STREET 1: C/O DENNIS M. LANFEAR
STREET 2: 333 TWIN DOLPHIN DR, SUITE 600
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: BioGenerics, Inc.
DATE OF NAME CHANGE: 20110210
4
1
doc1.xml
FORM 4
X0306
4
2020-02-19
0
0001512762
Coherus BioSciences, Inc.
CHRS
0001427569
Viret Jean-Frederic
COHERUS BIOSCIENCES, INC.
333 TWIN DOLPHIN DRIVE, SUITE 600
REDWOOD CITY
CA
94065
0
1
0
0
Chief Financial Officer
Common Stock, $0.0001 par value
2020-02-19
4
M
0
3159
10.05
A
50000
D
Common Stock, $0.0001 par value
2020-02-19
4
S
0
3159
22.3336
D
46841
D
Stock Option (Right to Buy)
10.05
2020-02-19
4
M
0
3159
0.00
D
2028-02-01
Common Stock
3159
101569
D
Includes 31,250 restricted stock units.
The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person.
The transaction was executed in multiple trades in prices ranging from $22.09 to $22.73, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
/s/ Jean-Frederic Viret
2020-02-21